Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Cervantes, 2014, How I treat myelofibrosis, Blood, 124, 2635, 10.1182/blood-2014-07-575373 Reiter, 2009, Molecular basis of myelodysplastic/myeloproliferative neoplasms, Haematologica, 94, 1634, 10.3324/haematol.2009.014001 Nangalia, 2013, Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2, N Engl J Med, 369, 2391, 10.1056/NEJMoa1312542 Verstovsek, 2012, A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis, N Engl J Med, 366, 799, 10.1056/NEJMoa1110557 Harrison, 2012, JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis, N Engl J Med, 366, 787, 10.1056/NEJMoa1110556 Verstovsek, 2015, Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I, Haematologica, 100, 479, 10.3324/haematol.2014.115840 Harrison, 2016, Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis, Leukemia, 30, 1701, 10.1038/leu.2016.148 Stein, 2015, Novel therapies for myelofibrosis, Leuk Lymphoma, 56, 2768, 10.3109/10428194.2015.1037762 Kantarjian, 2013, Outcome of patients (pts) with myelofibrosis (MF) after ruxolutinib (rux) therapy, Blood, 122, 1584, 10.1182/blood.V122.21.1584.1584 Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, 114, 937, 10.1182/blood-2009-03-209262 Cervantes, 2012, Prognostication in primary myelofibrosis, Curr Hematol Malig Rep, 7, 43, 10.1007/s11899-011-0102-1 Tefferi, 2013, Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European LeukemiaNet (ELN) consensus report, Blood, 122, 1395, 10.1182/blood-2013-03-488098 Mesa, 2011, Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial, Cancer, 117, 4869, 10.1002/cncr.26129 Schenker, 1980, Hepatic and Wernicke's encephalopathies: current concepts of pathogenesis, Am J Clin Nutr, 33, 2719, 10.1093/ajcn/33.12.2719 Pardanani, 2014, Definition and management of ruxolitinib treatment failure in myelofibrosis, Blood Cancer J, 4, e268, 10.1038/bcj.2014.84 Reilly, 2014, Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012, Br J Haematol, 167, 418, 10.1111/bjh.12985 Gupta, 2017, A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis, Haematologica, 102, 94, 10.3324/haematol.2016.148924 Pardanani, 2015, Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial, JAMA Oncol, 1, 643, 10.1001/jamaoncol.2015.1590 Pardanani, 2015, A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis, Blood Cancer J, 5, e335, 10.1038/bcj.2015.63 Shanavas, 2016, Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors, Biol Blood Marrow Transplant, 22, 432, 10.1016/j.bbmt.2015.10.005